Recent studies demonstrated that RYR2 was significantly mutated in multiple cancers, and RYR2 was reported to be a driver gene in cervical cancer, colon cancer, breast cancer, head and neck cancer, and lung adenocarcinoma (Wolff et al., 2018; Schmitt et al., 2019; Wang et al., 2019; Cimas et al., 2020; Wei et al., 2020). The gene discussed is RYR2; the disease is lung adenocarcinoma.